{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T08:43:12Z","timestamp":1772268192560,"version":"3.50.1"},"reference-count":34,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004881","name":"Instituto Mexicano del Seguro Social","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004881","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fundaci\u00f3n IMSS A.C., Mexico"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Direct Acting Antivirals (DAAs) represent a large improvement in the treatment of chronic hepatitis C, resulting in &lt;90% sustained virological response (SVR). There are no reports on the real-world DAA response for Mexico and few reports exist for Latin America. The aim of the study was to report SVR, and immediate benefits with the DAA treatments sofosbuvir, ledispavir, with\/without ribavirin (SOF\/LDV \u00b1\u00a0RBV) and ombitasvir, paritaprevir, ritonavir, dasabuvir with\/without RBV (OBV\/PTV\/r\/DSV \u00b1\u00a0RBV) in patients with viral genotype 1a or 1b, and who did not respond to previous peginterferon\/ribavirin (PegIFN\u03b12a+RBV) therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A descriptive, ambispective, longitudinal study was conducted. A cohort of 261 adult patients received PegIFN\u03b12a+RBV therapy before 2014; 167 (64%) did not respond, 83 of these were subsequently treated with SOF\/LDV \u00b1\u00a0RBV or OBV\/PTV\/r\/DSV \u00b1\u00a0RBV. Child-Pugh-Score (CPS), Fibrosis-4 (FIB-4), and AST to Platelet Ratio Index (APRI) were evaluated before and after treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SVR with PegIFN\u03b12a+RBV was 36%, and 97.5% with DAAs. CPS, FIB-4 and APRI improved significantly after DAA treatment, mainly because of liver transaminase reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>DAA treatment showed excellent SVR rates in Mexican patients who had not responded to PegIFN\u03b12a+RBV therapy. Improvement in CPS, FIB-4 and APRI without improvement in fibrosis was observed in cirrhotic and non-cirrhotic patients, as well as considerable reduction in liver transaminases, which suggests a reduction in hepatic necroinflammation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.7717\/peerj.12051","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T05:14:40Z","timestamp":1631855680000},"page":"e12051","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness, tolerability and safety of Direct Acting Antivirals in Mexican individuals with Hepatitis C virus genotype-1 and previous pegylated interferon and ribavirin therapy"],"prefix":"10.7717","volume":"9","author":[{"given":"Daniel","family":"Melendez-Mena","sequence":"first","affiliation":[{"name":"Centro Interdisciplinario de Posgrados, Facultad de Medicina, Universidad Popular Auton\u00f3ma del Estado de Puebla, Puebla, Puebla, Mexico"},{"name":"Servicio de Gastroenterolog\u00eda, Centro M\u00e9dico Nacional General de Divisi\u00f3n Manuel \u00c1vila Camacho, Instituto Mexicano del Seguro Social, Puebla, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel Angel","family":"Mendoza-Torres","sequence":"additional","affiliation":[{"name":"Centro Interdisciplinario de Posgrados, Facultad de Medicina, Universidad Popular Auton\u00f3ma del Estado de Puebla, Puebla, Puebla, Mexico"},{"name":"Servicio de Gastroenterolog\u00eda, Centro M\u00e9dico Nacional General de Divisi\u00f3n Manuel \u00c1vila Camacho, Instituto Mexicano del Seguro Social, Puebla, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Sede\u00f1o-Monge","sequence":"additional","affiliation":[{"name":"Decanato de Ciencias M\u00e9dicas, Universidad Popular Auton\u00f3ma del Estado de Puebla, Puebla, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor Hugo","family":"Garc\u00eda y Garc\u00eda","sequence":"additional","affiliation":[{"name":"Servicio de Gastroenterolog\u00eda, Centro M\u00e9dico Nacional General de Divisi\u00f3n Manuel \u00c1vila Camacho, Instituto Mexicano del Seguro Social, Puebla, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elain","family":"Rivera-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Decanato de Ciencias M\u00e9dicas, Universidad Popular Auton\u00f3ma del Estado de Puebla, Puebla, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"S\u00e1nchez-Reza","sequence":"additional","affiliation":[{"name":"Servicio de Gastroenterolog\u00eda, Centro M\u00e9dico Nacional General de Divisi\u00f3n Manuel \u00c1vila Camacho, Instituto Mexicano del Seguro Social, Puebla, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda del Carmen","family":"Baxin Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"Centro M\u00e9dico Nacional La Raza, Instituto Mexicano del Seguro Social, Ciudad de M\u00e9xico, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda","family":"Guzm\u00e1n-Flores","sequence":"additional","affiliation":[{"name":"Banco de Sangre, Centro M\u00e9dico Nacional General de Divisi\u00f3n Manuel \u00c1vila Camacho, Instituto Mexicano del Seguro Social, Puebla, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ygnacio","family":"Martinez-Laguna","sequence":"additional","affiliation":[{"name":"Instituto de Ciencias, Benemerita Universidad Aut\u00f3noma de Puebla, Puebla, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"Coronel Espinoza","sequence":"additional","affiliation":[{"name":"Hospital General Regional # 1, Instituto Mexicano del Seguro Social, Tar\u00edmbaro, Michoac\u00e1n, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iv\u00e1n","family":"Galindo-Santiago","sequence":"additional","affiliation":[{"name":"Laboratorio de Biolog\u00eda Molecular y Virolog\u00eda, Centro de Investigaci\u00f3n Biom\u00e9dica de Oriente, Instituto Mexicano del Seguro Social, Metepec, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Flores-Alonso","sequence":"additional","affiliation":[{"name":"Laboratorio de Biolog\u00eda Molecular y Virolog\u00eda, Centro de Investigaci\u00f3n Biom\u00e9dica de Oriente, Instituto Mexicano del Seguro Social, Metepec, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Vallejo-Ruiz","sequence":"additional","affiliation":[{"name":"Laboratorio de Biolog\u00eda Molecular y Virolog\u00eda, Centro de Investigaci\u00f3n Biom\u00e9dica de Oriente, Instituto Mexicano del Seguro Social, Metepec, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulina","family":"Cortes-Hernandez","sequence":"additional","affiliation":[{"name":"Laboratorio de Biolog\u00eda Celular, Centro de Investigaci\u00f3n Biom\u00e9dica de Oriente, Instituto Mexicano del Seguro Social, Metepec, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Reyes-Leyva","sequence":"additional","affiliation":[{"name":"Laboratorio de Biolog\u00eda Molecular y Virolog\u00eda, Centro de Investigaci\u00f3n Biom\u00e9dica de Oriente, Instituto Mexicano del Seguro Social, Metepec, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisca","family":"Sosa-Jurado","sequence":"additional","affiliation":[{"name":"Laboratorio de Biolog\u00eda Molecular y Virolog\u00eda, Centro de Investigaci\u00f3n Biom\u00e9dica de Oriente, Instituto Mexicano del Seguro Social, Metepec, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Santos-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Laboratorio de Biolog\u00eda Molecular y Virolog\u00eda, Centro de Investigaci\u00f3n Biom\u00e9dica de Oriente, Instituto Mexicano del Seguro Social, Metepec, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4443","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"key":"10.7717\/peerj.12051\/ref-1","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/bcp.13490","article-title":"Critical evaluation of causality assessment of herb-drug interactions in patients","volume":"84","author":"Awortwe","year":"2018","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.7717\/peerj.12051\/ref-2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/liv.13256","article-title":"Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index","volume":"37","author":"Bachofner","year":"2017","journal-title":"Liver International"},{"key":"10.7717\/peerj.12051\/ref-3","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jhep.2017.01.028","article-title":"Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real-world cohort","volume":"66","author":"Calleja","year":"2017","journal-title":"Journal of Hepatology"},{"key":"10.7717\/peerj.12051\/ref-4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.5604\/01.3001.0010.2717","article-title":"Treatment of chronic HCV infection with the new direct acting antivirals (DAA): first report of a real world experience in Southern Brazil","volume":"16","author":"Cheinquer","year":"2017","journal-title":"Annals of Hepatology"},{"key":"10.7717\/peerj.12051\/ref-5","doi-asserted-by":"publisher","first-page":"328","DOI":"10.5604\/16652681.1235473","article-title":"The direct-acting antivirals for hepatitis C virus and the risk for hepatocellular carcinoma","volume":"16","author":"Chinchilla-Lopez","year":"2017","journal-title":"Annals of Hepatology"},{"key":"10.7717\/peerj.12051\/ref-6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jhep.2015.08.015","article-title":"Efficacy and safety of ombitasvir\/paritaprevir\/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: the MALACHITE-I\/II trials","volume":"64","author":"Dore","year":"2016","journal-title":"Journal of Hepatology"},{"key":"10.7717\/peerj.12051\/ref-7","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1053\/j.gastro.2018.03.022","article-title":"Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection","volume":"154","author":"El-Sherif","year":"2018","journal-title":"Gastroenterology"},{"key":"10.7717\/peerj.12051\/ref-8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jare.2014.11.004","article-title":"New era for management of chronic hepatitis C virus using direct antiviral agents: a review","volume":"6","author":"Elbaz","year":"2015","journal-title":"Journal of Advanced Research"},{"key":"10.7717\/peerj.12051\/ref-9","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.4254\/wjh.v7.i26.2681","article-title":"Factors associated with the response to interferon-based antiviral therapies for chronic hepatitis C","volume":"7","author":"Enomoto","year":"2015","journal-title":"World Journal of Hepatology"},{"key":"10.7717\/peerj.12051\/ref-10","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1177\/2050640618791053","article-title":"Short-term histological evaluations after achieving a sustained virologic response to direct-acting antiviral treatment for chronic hepatitis C","volume":"6","author":"Enomoto","year":"2018","journal-title":"United European Gastroenterology Journal"},{"key":"10.7717\/peerj.12051\/ref-11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/MEG.0000000000001250","article-title":"Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis","volume":"31","author":"Essa","year":"2019","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"10.7717\/peerj.12051\/ref-12","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/apt.13790","article-title":"Real-world effectiveness and safety of ombitasvir\/paritaprevir\/ritonavir +\/- dasabuvir +\/- ribavirin in hepatitis C: AMBER study","volume":"44","author":"Flisiak","year":"2016","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.7717\/peerj.12051\/ref-13","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1097\/MEG.0000000000001400","article-title":"Clinical impact of serum alpha-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals","volume":"31","author":"Fouad","year":"2019","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"10.7717\/peerj.12051\/ref-14","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrgastro.2016.60","article-title":"Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights","volume":"13","author":"Gotte","year":"2016","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"10.7717\/peerj.12051\/ref-15","doi-asserted-by":"publisher","first-page":"e0134839","DOI":"10.1371\/journal.pone.0134839","article-title":"Benefit of treatment individualization in patients with chronic hepatitis C receiving peginterferon alfa-2a and ribavirin in a large noninterventional cohort study","volume":"10","author":"Hofmann","year":"2015","journal-title":"PLOS ONE"},{"key":"10.7717\/peerj.12051\/ref-16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.bjid.2018.06.004","article-title":"Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil","volume":"22","author":"Holzmann","year":"2018","journal-title":"Brazilian Journal of Infectious Diseases"},{"key":"10.7717\/peerj.12051\/ref-17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12876-019-0973-5","article-title":"Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents","volume":"19","author":"Hsu","year":"2019","journal-title":"BMC Gastroenterology"},{"key":"10.7717\/peerj.12051\/ref-18","volume-title":"Informe al ejecutivo federal y al congreso de la uni\u00f3n sobre la situaci\u00f3n financiera y los riesgos del Instituto Mexicano del Seguro Social 2017-2018","author":"Instituto Mexicano\u00a0del Seguro\u00a0Social","year":"2018"},{"key":"10.7717\/peerj.12051\/ref-19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.20411\/pai.v3i1.242","article-title":"Soluble markers of immune activation differentially normalize and selectively associate with improvement in AST, ALT, albumin, and transient elastography during IFN-free HCV therapy","volume":"3","author":"Kostadinova","year":"2018","journal-title":"Pathogens and Immunity"},{"key":"10.7717\/peerj.12051\/ref-20","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/S1665-2681(19)30976-7","article-title":"Hepatitis C virus infection in patients and family members attending two primary care clinics in Puebla, Mexico","volume":"13","author":"Lopez-Colombo","year":"2014","journal-title":"Annals of Hepatology"},{"key":"10.7717\/peerj.12051\/ref-21","doi-asserted-by":"publisher","first-page":"922","DOI":"10.12998\/wjcc.v6.i15.922","article-title":"Current trends of liver cirrhosis in Mexico: similitudes and differences with other world regions","volume":"6","author":"Mendez-Sanchez","year":"2018","journal-title":"World Journal of Clinical Cases"},{"key":"10.7717\/peerj.12051\/ref-22","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1002\/jmv.24816","article-title":"Ombitasvir\/paritaprevir\/ritonavir\/dasabuvir +\/- ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America","volume":"89","author":"Mendizabal","year":"2017","journal-title":"Journal of Medical Virology"},{"key":"10.7717\/peerj.12051\/ref-23","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","article-title":"Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial","volume":"15","author":"Mizokami","year":"2015","journal-title":"The Lancet Infectious Diseases"},{"key":"10.7717\/peerj.12051\/ref-24","doi-asserted-by":"publisher","first-page":"e1234","DOI":"10.1097\/MD.0000000000001234","article-title":"Sustained virologic response to a dual peginterferon alfa-2a and ribavirin in treating chronic hepatitis C infection: a retrospective cohort study","volume":"94","author":"Naing","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.7717\/peerj.12051\/ref-25","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00535-016-1290-1","article-title":"NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b","volume":"52","author":"Ogawa","year":"2017","journal-title":"Journal of Gastroenterology"},{"key":"10.7717\/peerj.12051\/ref-26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/jvh.12637","article-title":"Effectiveness and safety of ombitasvir, paritaprevir, ritonavir +\/- dasabuvir +\/- ribavirin: an early access programme for Spanish patients with genotype 1\/4 chronic hepatitis C virus infection","volume":"24","author":"Perello","year":"2017","journal-title":"Journal of Viral Hepatitis"},{"key":"10.7717\/peerj.12051\/ref-27","doi-asserted-by":"publisher","first-page":"188","DOI":"10.5604\/16652681.1231562","article-title":"Combination of ledipasvir and sofosbuvir for treatment of hepatitis C virus genotype 1 infection: systematic review and meta-analysis","volume":"16","author":"Rezaee-Zavareh","year":"2017","journal-title":"Annals of Hepatology"},{"issue":"Suppl 1","key":"10.7717\/peerj.12051\/ref-28","first-page":"5","article-title":"Mexican consensus on the diagnosis and management of hepatitis C infection","volume":"14","author":"Sanchez-Avila","year":"2015","journal-title":"Annals of Hepatology"},{"key":"10.7717\/peerj.12051\/ref-29","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3855\/jidc.5284","article-title":"Responses to peginterferon alfa-2a vs alfa-2b plus ribavirin in a Mexican population with chronic hepatitis C","volume":"9","author":"Sandoval-Ramirez","year":"2015","journal-title":"The Journal of Infection in Developing Countries"},{"key":"10.7717\/peerj.12051\/ref-30","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1053\/j.gastro.2016.08.004","article-title":"Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response","volume":"151","author":"Terrault","year":"2016","journal-title":"Gastroenterology"},{"key":"10.7717\/peerj.12051\/ref-31","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1186\/s40064-016-2190-9","article-title":"Simeprevir with peginterferon\/ribavirin for patients with hepatitis C virus genotype 1: high frequency of viral relapse in elderly patients","volume":"5","author":"Watanabe","year":"2016","journal-title":"Springerplus"},{"key":"10.7717\/peerj.12051\/ref-32","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression","volume":"67","author":"Waziry","year":"2017","journal-title":"Journal of Hepatology"},{"key":"10.7717\/peerj.12051\/ref-33","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/jvh.12708","article-title":"Real-world experience with the all-oral, interferon-free regimen of ombitasvir\/paritaprevir\/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry","volume":"24","author":"Welzel","year":"2017","journal-title":"Journal of Viral Hepatitis"},{"key":"10.7717\/peerj.12051\/ref-34","author":"World Health\u00a0Organization","year":"2017","journal-title":"Global hepatitis report, 2017"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/12051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/12051.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/12051.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/12051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T05:14:50Z","timestamp":1631855690000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/12051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":34,"alternative-id":["10.7717\/peerj.12051"],"URL":"https:\/\/doi.org\/10.7717\/peerj.12051","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.7287\/peerj.12051v0.1\/reviews\/1","asserted-by":"object"},{"id-type":"doi","id":"10.7287\/peerj.12051v0.1\/reviews\/2","asserted-by":"object"},{"id-type":"doi","id":"10.7287\/peerj.12051v0.2\/reviews\/1","asserted-by":"object"},{"id-type":"doi","id":"10.7287\/peerj.12051v0.2\/reviews\/2","asserted-by":"object"}]},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,17]]},"article-number":"e12051"}}